1
|
|
2
|
|
3
|
Affiliation(s)
- J R Vane
- Wellcome Research Laboratories, Langley Court, Beckenham, Kent, BR3 3BS, UK
| |
Collapse
|
4
|
Abstract
Since the 1930s and the discovery by von Euler of a vasoactive, lipid-soluble substance that he erroneously assumed was generated by the prostate gland and therefore should be called "prostaglandin," the family of prostaglandins has grown to some 90 substances. These lipid mediators are derived from arachidonic acid in the "arachidonic acid cascade." In 1976, while looking for the enzyme that generates the unstable prostanoid thromboxane A2 from arachidonic acid, Moncada and Vane discovered prostaglandin I2 and renamed it "prostacyclin." Prostacyclin is the main product of arachidonic acid in all vascular tissues tested to date and strongly vasodilates all vascular beds studied. It is also the most potent endogenous inhibitor of platelet aggregation yet discovered, both inhibiting aggregation and dispersing existing aggregates. It acts through activation of adenylate cyclase, leading to increased levels of cyclic adenosine monophosphate. It also appears to have a "cytoprotective" activity, as yet not completely understood. Its effects are short-lasting, disappearing within 30 minutes of cessation of infusion. A stable, freeze-dried preparation of prostacyclin (epoprostenol) is available for administration to humans, and several analogs with therapeutically desirable characteristics are currently being clinically tested and should become commercially available soon. Clinical application of prostacyclin is bedeviled by 2 characteristics: it is pharmacologically unstable, so care must be taken in its use, and the correct dosage regimens have not yet been established.
Collapse
Affiliation(s)
- J R Vane
- William Harvey Research Institute, St. Bartholomew's Hospital Medical College, London, United Kingdom
| | | |
Collapse
|
5
|
Fessatidis IT, Brannan JJ, Taylor KM, Kanellaki-Kyparissi M, Abdulla AK, Olsen EC. Effect of prostacyclin PGI2 on cardiopulmonary bypass-induced lung injury. Perfusion 1994; 9:23-33. [PMID: 8161864 DOI: 10.1177/026765919400900105] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Lung injury produced by cardiopulmonary bypass (CPB) is clinically characterized as postperfusion pulmonary dysfunction syndrome. The roles of humoral factors, altered perfusion modes and the occurrence of diffuse microembolism have been subjects of a number of studies. This paper presents the effectiveness of a platelet inhibiting drug, PGI2 in preventing occlusive microaggregates in the pulmonary circulation. In a series of experimental dog studies using a PGI2 dosage protocol of 10 ng/kg/minute for 30 minutes prior to the onset of CPB followed by 20 mg/kg/minute during CPB, the following effects have been observed: 1) Preservation of platelet numbers during CPB (p < 0.01 versus controls; n = 16). 2) Significant reduction in platelet aggregation during CPB (p < 0.01; n = 16). 3) Insignificant hypotensive effect at normal levels of peripheral vascular resistance (n = 16). 4) Occlusive fibrin, leucocytes and small platelet-based microaggregates obstructing pulmonary arterioles in six of the seven control dogs but in none of the dogs receiving PGI2 infusion. 5) No evidence of perivascular or intra-alveolar oedema, interstitial inflammatory cell infiltrates or haemorrhage was seen in either group of dogs. The controversy existing in relation to the possible therapeutic role of PGI2 and, in particular, its ability to prevent occlusive microaggregates in the arterioles and capillaries of vital organs should encourage further clinical studies of PGI2 and its derivatives during cardiac surgery.
Collapse
Affiliation(s)
- I T Fessatidis
- Department of Cardiac Surgery, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK
| | | | | | | | | | | |
Collapse
|
6
|
Arima T, Gennda T, Ueda K, Hatanaka M, Omoto R, Matsumoto I. The effects of a prostacyclin analog OP-41483 on pulmonary oxygen toxicity in an isolated heart-lung autoperfusion model. PROSTAGLANDINS 1989; 37:33-51. [PMID: 2655011 DOI: 10.1016/0090-6980(89)90030-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Using an isolated canine heart-lung autoperfusion model, the effect of prostacyclin analog (OP-41483) on pulmonary oxygen toxicity was investigated. Twenty-four mongrel dogs were divided into four groups. Groups 1 and 2 inspired oxygen at concentrations (FiO2) of 0.95 and 0.6, respectively, while groups 3 and 4 received OP-41483 (0.1 micrograms/kg/min) in addition to FiO2 of 0.95 and 0.6. Autoperfusion was performed for five hours, and during the experiments the systolic blood pressure was maintained at 100 mmHg and the cardiac output at 40 ml/kg/min. After five hours of perfusion, PaO2 decreased significantly (P less than 0.01) from 410 +/- 49 mmHg to 237 +/- 38 mmHg in group 1, and also decreased significantly (P less than 0.01) from 368 +/- 44 mmHg to 243 +/- 26 mmHg in group 2. However, no significant changes in PaO2 were observed in groups 3 and 4. The pathological examinations clearly revealed perivascular edema and vascular dilation in groups 1 and 2, whereas no abnormal pathological findings were seen in groups 3 and 4. The above results indicate that OP-41483, when administered at the low dose of 0.1 micrograms/kg/min, induces no circulatory changes and exerts an effective action with respect to the prevention of pulmonary edema.
Collapse
Affiliation(s)
- T Arima
- Dept. of Anesthesiology and Surgery, Saitama Medical School, Japan
| | | | | | | | | | | |
Collapse
|
7
|
Arén C, Badr G, Feddersen K, Rådegran K. Somatosensory evoked potentials and cerebral metabolism during cardiopulmonary bypass with special reference to hypotension induced by prostacyclin infusion. J Thorac Cardiovasc Surg 1985. [DOI: 10.1016/s0022-5223(19)38665-9] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Addonizio VP, Fisher CA, Jenkin BK, Strauss JF, Musial JF, Edmunds LH. Iloprost (ZK36374), a stable analogue of prostacyclin, preserves platelets during simulated extracorporeal circulation. J Thorac Cardiovasc Surg 1985. [DOI: 10.1016/s0022-5223(19)38702-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
9
|
Feddersen K, Aurell M, Delin K, Häggendal J, Arén C, Rådegran K. Effects of cardiopulmonary bypass and prostacyclin on plasma catecholamines, angiotensin II and arginine-vasopressin. Acta Anaesthesiol Scand 1985; 29:224-30. [PMID: 3883684 DOI: 10.1111/j.1399-6576.1985.tb02190.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Infusion of prostacyclin during cardiopulmonary bypass (CPB) reduces platelet activation, diminishes postoperative blood loss and decreases arterial blood pressure. In spite of continuous prostacyclin infusion, there is a delayed gradual rise in arterial pressure and resistance from low initial levels. We measured epinephrine (E), norepinephrine (NE), serotonin (5-HT), angiotensin II (ATII) and arginine-vasopressin (AVP) in plasma and carried out hemodynamic studies in 19 patients operated for coronary vascular disease. Eight patients served as a control group and were subjected to routine CPB. Eleven patients received prostacyclin 50 ng/kg/min during CPB. E and NE increased four- to sixfold during CPB from about 0.5 ng/ml (P less than 0.001). There was no difference between the groups. During CPB AVP increased sixfold from about 20 pg/ml in both groups (P less than 0.001), decreased early after CPB and increased again to high levels 3 h after CPB. The combined action of E, NE and AVP is of likely importance for the rise in systemic vascular resistance and/or need of vasodilation during CPB in the control group. ATII did not increase in the control group, but increased fourfold to about 20 pg/ml (P less than 0.01) during CPB in the prostacyclin group. The addition of AT II to E, NE and AVP seems responsible for the gradual return of arterial pressure and resistance during prostacyclin infusion. Postoperative hypertension and/or need of vasodilation 3 h after CPB was associated with high AVP levels in both groups. Hypotension caused by prostacyclin infusion did not increase E, NE or AVP above levels produced by CPB and moderate hypotension alone.
Collapse
|
10
|
Sollevi A, Torssell L, Fredholm BB, Settergren G, Blombäck M. Adenosine spares platelets during cardiopulmonary bypass in man without causing systemic vasodilatation. SCANDINAVIAN JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY 1985; 19:155-9. [PMID: 4048886 DOI: 10.3109/14017438509102711] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The effect of infusing adenosine during cardiopulmonary bypass (CPB) on platelet count and mean arterial blood pressure (MABP) was studied in 13 patients (age 42-74), with 12 patients (age 47-66) as controls. Adenosine infusion (0.1 mg/kg/min in a central vein) caused a ten- to twentyfold increase of the adenosine concentration in the venous blood to the oxygenator, while the arterial levels were close to basal values (0.3 +/- 0.1 microM). The platelet count was significantly higher in the treated than in the placebo group during and 30 min after CPB, but not on the postoperative day. The groups did not differ with regard to the postoperative blood loss from tube drainage. Adenosine did not cause major systemic vasodilation (MABP less than 30 mmHg) in any case, and the blood pressure levels showed no intergroup difference during CPB. However, seven control patients but none in the adenosine group required vasodilator treatment (sodium nitroprusside) during CPB to prevent MABP from exceeding 70 mmHg. We conclude that adenosine infusion during CPB in man spares platelets, with minor changes in blood pressure.
Collapse
|
11
|
Arén C, Blomstrand C, Wikkelsö C, Radegran K. Hypotension induced by prostacyclin treatment during cardiopulmonary bypass does not increase the risk of cerebral complications. J Thorac Cardiovasc Surg 1984. [DOI: 10.1016/s0022-5223(19)35442-x] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
12
|
DiSesa VJ, Huval W, Lelcuk S, Jonas R, Maddi R, Lee-Son S, Shemin RJ, Collins JJ, Hechtman HB, Cohn LH. Disadvantages of prostacyclin infusion during cardiopulmonary bypass: a double-blind study of 50 patients having coronary revascularization. Ann Thorac Surg 1984; 38:514-9. [PMID: 6388516 DOI: 10.1016/s0003-4975(10)64194-x] [Citation(s) in RCA: 37] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Prostacyclin (PGI2) has been suggested for use in cardiopulmonary bypass (CPB) because of its positive effects on platelet number and function. Fifty patients who underwent coronary artery bypass grafting using a bubble oxygenator received heparin, 3 mg per kilogram of body weight, and then were randomly assigned to receive PGI2, 25 ng/kg/min, beginning 5 minutes before and until the end of CPB (26 patients) or a placebo (24 patients). Both groups were similar in sex, age, heparin dose, protamine dose, and CPB time. During CPB, mean arterial pressure fell significantly with PGI2 (76 +/- 2 mm Hg to 53 +/- 2 mm Hg; p less than 0.05) and necessitated pressor substances. Platelet counts fell significantly in both groups with the start of CPB, but after 60 minutes were similar in both groups (118 +/- 9 X 10(3) versus 130 +/- 8 X 10(3); not significant [NS]) and were unchanged 3 hours after CPB. Total chest tube output was 647 +/- 51 ml (placebo group) versus 576 +/- 34 ml (PGI2 group) (NS); 18 of the patients given PGI2 required 26 transfusions compared with 16 transfusions in 8 of the patients given a placebo (p less than 0.05). In PGI2 patients, arterial oxygen tension on 100% oxygen fell from 281 +/- 18 mm Hg before CPB to 223 +/- 17 mm Hg immediately after CPB (p less than 0.05). The placebo patients did not show a change in this variable.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
13
|
Vane JR. Nobel lecture. Adventures and excursions in bioassay--the stepping stones to prostacyclin. Postgrad Med J 1983; 59:743-58. [PMID: 6361717 PMCID: PMC2417791 DOI: 10.1136/pgmj.59.698.743] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
14
|
Heinrich D, Schleussner E, Wagner WL, Sellmann-Richter R, Hehrlein FW. Prostacyclin in aortocoronary bypass surgery: a double-blind, placebo-controlled study. Thromb Res 1983; 32:409-26. [PMID: 6362060 DOI: 10.1016/0049-3848(83)90093-2] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
In a double-blind, placebo-controlled trial of 40 patients requiring aortocoronary vene transplant surgery, prostacyclin (PGI2) was infused in a dose of 8 ng/kg/min throughout cardiopulmonary bypass. When compared with the placebo-group, the patients treated with PGI2 were found to have significantly higher platelet counts 60(2) and 90 minutes after onset of extra-corporeal circulation (EC). Although this platelet preservation by PGI2 was accompanied by less degranulation of alpha-granula, total antithrombin III (AT III) as well as active AT III and factor Xa inhibitory activity did show comparable results in both treatment groups. In the early phase of EC coagulation factors (fibrinogen, prothrombin and factor VII) exhibited a trend in favour of higher plasma levels in the PGI2-treated group. The same results were found for plasminogen. F VIII-related antigen and complement factors (C3, C4, C3 activator) did not show any difference between the two treatment groups. Bleeding times, blood loss and renal function also did not exhibit any significant differences between the two groups of patients. Except for one control (60 minutes after onset of EC) hemodynamic parameters were not significantly different between the two patient groups. Whether the trend in favour of a lower mortality in PGI2-treated patients can be confirmed, will be up to further studies with greater numbers of patients.
Collapse
|
15
|
Vane JR. Adventures and Excursions in Bioassay: The Stepping Stones to Prostacyclin (Noble Lecture). ACTA ACUST UNITED AC 1983. [DOI: 10.1002/anie.198307413] [Citation(s) in RCA: 35] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
|
16
|
Vane JR. Adventures and excursions in bioassay: the stepping stones to prostacyclin. Nobel Lecture, 8 December 1982. Biosci Rep 1983; 3:683-711. [PMID: 6354296 DOI: 10.1007/bf01120983] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
|
17
|
Vane JR. Nobel lecture, 8th December 1982. Adventures and excursions in bioassay: the stepping stones to prostacyclin. Br J Pharmacol 1983; 79:821-38. [PMID: 6360277 PMCID: PMC2044916 DOI: 10.1111/j.1476-5381.1983.tb10020.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
|
18
|
Putnam EA, Manners JM. Vascular resistance during cardiopulmonary bypass. Its effect on cardiac performance in the immediate post-bypass period. Anaesthesia 1983; 38:635-43. [PMID: 6603176 DOI: 10.1111/j.1365-2044.1983.tb12154.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
A clinical study was undertaken to measure changes in systemic vascular resistance during cardiopulmonary bypass in 56 adults. Forty-five patients showed a rise in systemic vascular resistance and 77% required no inotropic support in the immediate post-bypass period. Eleven of the 33 patients undergoing valve replacement surgery showed only a small increase or an actual decrease in systemic vascular resistance and required inotropic support. These results were statistically significant. Factors affecting cardiac performance are discussed.
Collapse
|
19
|
|